AstraZeneca: Influenza, Human trials

The registry lists 45 Influenza, Human studies with AstraZeneca as lead sponsor. 1 are open to participants now and 16 have results posted.

Phase 1 4Phase 2 14Phase 3 14Phase 4 12No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental OxygenRecruitingNCT05624450Phase 3
• D2560C00015 FluMist Annual Safety Study 2018CompletedNCT03564444Phase 4Results posted
• Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 SeasonCompletedNCT03158038Phase 4Results posted
• Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of AgeCompletedNCT03143101Phase 4Results posted
• Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 SeasonCompletedNCT02743117Phase 4Results posted
• A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated InfluenzaCompletedNCT02603952Phase 1/2Results posted
• Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 SeasonCompletedNCT02473510Phase 4Results posted
• Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in AdultsCompletedNCT01859143Phase 4Results posted
• A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in AdultsCompletedNCT01579916Phase 4Results posted
• A Study to Evaluate the Safety of HIN1 Monovalent Vaccine (MEDI3414) in Children 2 to 17 Years of AgeCompletedNCT00946101Phase 4Results posted
• A Prospective Study to Evaluate the Safety of a New Monovalent Intranasal Influenza VaccineCompletedNCT00873912Phase 4Results posted
• A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of AgeCompletedNCT00860067Phase 2/3Results posted
• Assessing Choice in the Employer Setting (ACES) StudyCompletedNCT00808808Results posted
• A Prospective Study to Evaluate the Safety of a New Trivalent Intranasal Influenza VaccineCompletedNCT00677820Phase 4Results posted
• A Phase 2 Study to Evaluate Immune Responses of FluMist®CompletedNCT00461981Phase 2Results posted
• A Study to Evaluate the Shedding and Safety of Trivalent Influenza Virus Vaccine Live, Intranasal in Infants and Young ChildrenCompletedNCT00344305Phase 2Results posted
• Safety Study to Evaluate FluMist in Immunocompromised ChildrenCompletedNCT00112112Phase 1Results posted
• A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)Active, not recruitingNCT07128615Phase 1/2
• Uptake of the Childhood Live Attenuated Influenza Vaccine (LAIV) and Influenza-related Healthcare Resource Use in England During the 2012 to 2022 Flu Seasons; a Retrospective, Observational Study in the CPRD and HES DatabasesCompletedNCT06077045
• Evaluation of the Safety and Efficacy of a Monoclonal Antibody to Treat InfluenzaWithdrawnNCT03903718Phase 2
• Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults Who Are Hospitalized With Type A Influenza.WithdrawnNCT03028909Phase 2
• Phase 1 Placebo-controlled,Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of MEDI8852 in AdultsCompletedNCT02350751Phase 1
• A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2-17 Years of AgeTerminatedNCT01997450
• Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of AgeCompletedNCT01985997
• Study to Evaluate the Safety of a Monovalent Vaccine of a New 6:2 Reassortant in Healthy Adults (AV024)CompletedNCT00240877Phase 3
• Trial To Assess Safety And Efficacy Of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) In Adults Aged 60 Years And OlderCompletedNCT00217230Phase 3
• Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, and Varicella Vaccines Administered Concurrently to Healthy ChildrenCompletedNCT00192491Phase 3
• Trial to Evaluate the Immune Response to OPV When Administered Concomitantly With CAIV-T to Healthy Children.CompletedNCT00192426Phase 3
• Trial to Compare the Safety, Tolerability, and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Inactivated, Influenza Vaccine, Trivalent, Types A & B, in Adults Aged 60 Years and Older Against Culture-confirmed InfluenzaCompletedNCT00192413Phase 3
• Trial to Investigate Viral Shedding in Healthy Children Vaccinated With Vaccine Virus Liquid (CAIV-T)CompletedNCT00192387Phase 2
• Trial of the Safety, Transmissibility, and Phenotypic and Genotypic Stability of Influenza Virus Vaccine,(CAIV-T), in Children Who Attend Day Care. (Final Report Version 2.0)CompletedNCT00192361Phase 3
• Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy ChildrenCompletedNCT00192322Phase 2
• Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.CompletedNCT00192309Phase 2
• Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold- Adapted (CAIV-T) in Healthy Children Attending Day Care CentersCompletedNCT00192283Phase 3
• Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine,(CAIV-T)CompletedNCT00192231Phase 3
• Study to Evaluate the Effectiveness of FluMist Vaccination in a School-Based Intervention ProgramCompletedNCT00192218Phase 4
• Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy AdultsCompletedNCT00192192Phase 3
• A Phase II, Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine, CAIV-T in Healthy Children and Adolescents Ages 6 to Less Than 18 Years.CompletedNCT00192179Phase 2
• Trial to Assess Safety, Efficacy, Tolerability and Immunogenicity of Influenza Virus Vaccine, Liquid Formulation (CAIV-T), Administered Concomitantly With a Combination Live, Attenuated, Mumps, Measles, and Rubella Vaccine in Healthy Children Aged 11 - 24 MonthsCompletedNCT00192166Phase 2
• Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine(CAIV-T)in Healthy Adults Aged 18 to 59 and Healthy Adults Aged 60 Years and OlderCompletedNCT00192153Phase 2
• Trial to Assess the Shedding,Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of AgeCompletedNCT00192140Phase 4
• Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy AdultsCompletedNCT00192127Phase 3
• Trivalent, Live, Cold Adapted Influenza Vaccine (CAIV-T) Against Inactivated Influenza Vaccine (TIV) in Children 6-59 Months of AgeCompletedNCT00128167Phase 3
• Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy AdultsCompletedNCT00125944Phase 3
• Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV)CompletedNCT00111579Phase 2